Sugi Predict

Sugi Predict / Compounds / SCHEMBL505455

SCHEMBL505455

SCHEMBL505455

O=C(O)c1ccc(-c2ccccc2)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LDHA P00338 3/20 1.00
▸ P4HA1 P13674 3/20 0.73
▸ P4HTM Q9NXG6 2/20 0.73
▸ BAZ2B Q9UIF8 1/20 0.67
▸ HPGDS O60760 1/20 0.59
▸ NPC1 O15118 3/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ MIF P14174 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ GABRP O00591 1/20 0.52
▸ GABRD O14764 1/20 0.52
▸ GABRA1 P14867 1/20 0.52
▸ GABRB1 P18505 1/20 0.52
▸ GABRG2 P18507 1/20 0.52
▸ GABRB3 P28472 1/20 0.52
▸ GABRA5 P31644 1/20 0.52
▸ GABRA3 P34903 1/20 0.52
▸ GABRA2 P47869 1/20 0.52
▸ GABRB2 P47870 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18045639 0.98 LDHA (0.96) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL8521766 0.92 LDHA (0.85) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL28312333 0.90 LDHA (0.81) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL30753641 0.90 LDHA (0.81) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL503140 0.89 LDHA (0.79) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL27584594 0.88 LDHA (0.79) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL31243316 0.87 LDHA (0.77) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL29465714 0.87 LDHA (0.77) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL28704917 0.87 LDHA (0.77) LDHAP4HA1P4HTMBAZ2BHPGDS
SCHEMBL22332190 0.86 P4HA1 (0.76) LDHAP4HA1P4HTMBAZ2BHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126392-A1 VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-06-20 — — WO claimed
EP-4385995-A1 VECTORIZED NHC IRIDIUM(III) COMPLEXES AND USE THEREOF IN PHOTODYNAMIC THERAPY AND/OR DIAGNOSTIC Centre National de la Recherche Scientifique (FR) 2024-06-19 — — EP claimed
JP-2004520404-A — — 2004-07-08 — — JP claimed
EP-1363644-A2 MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES Can-Fite Biopharma Ltd. (IL) 2003-11-26 — — EP claimed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP claimed
WO-2002066020-A2 MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES CAN-FITE BIOPHARMA LTD. (IL) 2002-08-29 — — WO claimed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 — — EP claimed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 — — WO claimed
CN-122029148-A N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases 阿勒泰治疗公司 2026-05-12 — — CN disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20260070878-A1 TNKS2 INHIBITORS UNIV CORNELL (US) 2026-03-12 — — US disclosed
US-20250353833-A1 DPP9 BINDING COMPOUNDS UNIV ANTWERPEN (BE) 2025-11-20 — — US disclosed
EP-4628487-A2 PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO Emory University (US) 2025-10-08 — — EP disclosed
EP-3941916-B1 PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO UNIV EMORY (US) 2025-10-01 — — EP disclosed
EP-0778835-A1 7-AZABICYCLO 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS UNIVERSITY OF VIRGINIA (US) 1997-06-18 — — EP disclosed
WO-1996006093-A1 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS UNIVERSITY OF VIRGINIA (US) 1996-02-29 — — WO disclosed
EP-0691971-A1 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1996-01-17 — — EP disclosed
WO-1994022868-A1 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1994-10-13 — — WO disclosed
CN-1024317-C Antifungal agents based on amides containing phenyl group RHONE POULENC AGROCHIMIE (FR) 1994-04-27 — — CN disclosed
CN-1040792-A ANTIFUNGAL AGENTS BASED ON AMIDES CONTAINING PHENYL GROUP RHONE POULENC AGROCHIMIE (FR) 1990-03-28 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B LDHA 3483/4885P4HA1 2432/4885P4HTM 1407/4885
US-20260070878-A1 TNKS2 INHIBITORS TNKS, TNKS2, TNK1 LDHA 2035/4885P4HA1 1075/4885P4HTM 1434/4885
US-20250353833-A1 DPP9 BINDING COMPOUNDS DPP9, DPP7, DPP3 LDHA 865/4885P4HA1 829/4885P4HTM 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.